跳至主要内容
临床试验/NCT02965963
NCT02965963已完成不适用

The Effect of Dopamine on Pulmonary Diffusion and Capillary Blood Volume During Exercise

University of Alberta1 个研究点 分布在 1 个国家目标入组 49 人开始时间: 2016年12月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
49
试验地点
1
主要终点
Diffusing Capacity for Carbon Monoxide

研究概览

简要总结

The purpose of this study is to examine the effect of dopamine infusion and dopamine-2 receptor blockade on pulmonary capillary blood volume, diffusion, and the hemodynamic variables of pulmonary artery pressure, cardiac output, and pulmonary vascular resistance during exercise. Secondarily, this study will examine the effect of dopamine infusion and dopamine-2 receptor blockade on exercise tolerance.

详细描述

  1. Study Objectives

The primary objective of this study is to examine the effect of dopamine infusion and dopamine-2 receptor blockade on pulmonary capillary blood volume, diffusion, and the hemodynamic variables of pulmonary artery pressure, cardiac output, and pulmonary vascular resistance during exercise. Secondarily, this study will examine the effect of dopamine infusion and dopamine-2 receptor blockade on exercise tolerance. 2. Background

To meet the increased oxygen demand required for exercise, pulmonary diffusing capacity (DLCO) must increase in order to avoid a drop in arterial oxygenation and early exercise termination. Enhanced DLCO during exercise is achieved by expanding pulmonary capillary blood volume (Vc) and diffusing membrane capacity (Dm) through recruitment and distention of the pulmonary capillaries, effectively increasing the surface area for diffusion. Recruitment and distention of the pulmonary capillaries decreases pulmonary vascular resistance (PVR), increasing pulmonary blood flow (Q) while limiting the rise in pulmonary artery pressure (PAP) with exercise.

In health, pharmacological interventions are not believed to affect PAP during exercise. However, dopamine, a pulmonary vasodilator, may help to regulate PAP during exercise. Specifically, dopamine appears important for a normal cardiovascular exercise response, as Metoclopramide (pulmonary dopamine-2-receptor antagonist) decreases maximal Q and exercise tolerance (1). These results suggest that dopamine may modulate Vc during exercise via pulmonary smooth muscle regulation, subsequently affecting PVR, PAP, Q and exercise tolerance. However, how dopamine regulates DLCO, Vc, Q, and exercise tolerance is unknown.

Purpose: The purpose of this study is to examine the effect of a dopamine agonist and a dopamine-2-receptor antagonist on DLCO, Vc, PAP, PVR, Q, and exercise tolerance.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Basic Science
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 50 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Physically active (exercising >2 times per week)
  • BMI < 30kg/m2
  • No known cardiac or pulmonary disease

排除标准

  • Known cardiac or pulmonary diseases / abnormalities
  • Use of medications that could interfere with dopaminergic pathways (i.e. dopaminergic agonists / antagonists, alcohol, central nervous system depressants, and serotonergic drugs)
  • BMI > 30kg/m2
  • Female subjects must not be pregnant

研究组 & 干预措施

Metoclopramide

Experimental

Dependent variables measured with oral metoclopramide ingestion at rest, 60%, and 85% of VO2max

干预措施: Exercise - 60% (Other)

Dopamine

Experimental

Dependent variables measured with intravenous low dose dopamine infusion at rest, 60%, and 85% of VO2max

干预措施: Dopamine (Drug)

Dopamine

Experimental

Dependent variables measured with intravenous low dose dopamine infusion at rest, 60%, and 85% of VO2max

干预措施: Rest (Other)

Dopamine

Experimental

Dependent variables measured with intravenous low dose dopamine infusion at rest, 60%, and 85% of VO2max

干预措施: Exercise - 60% (Other)

Dopamine

Experimental

Dependent variables measured with intravenous low dose dopamine infusion at rest, 60%, and 85% of VO2max

干预措施: Exercise - 85% (Other)

Metoclopramide

Experimental

Dependent variables measured with oral metoclopramide ingestion at rest, 60%, and 85% of VO2max

干预措施: Metoclopramide (Drug)

Metoclopramide

Experimental

Dependent variables measured with oral metoclopramide ingestion at rest, 60%, and 85% of VO2max

干预措施: Rest (Other)

Metoclopramide

Experimental

Dependent variables measured with oral metoclopramide ingestion at rest, 60%, and 85% of VO2max

干预措施: Exercise - 85% (Other)

Placebos

Experimental

Dependent variables measured with orally ingested placebo pill and intravenous saline at rest, 60%, and 85% of VO2max

干预措施: Placebos (Drug)

Placebos

Experimental

Dependent variables measured with orally ingested placebo pill and intravenous saline at rest, 60%, and 85% of VO2max

干预措施: Rest (Other)

Placebos

Experimental

Dependent variables measured with orally ingested placebo pill and intravenous saline at rest, 60%, and 85% of VO2max

干预措施: Exercise - 60% (Other)

Placebos

Experimental

Dependent variables measured with orally ingested placebo pill and intravenous saline at rest, 60%, and 85% of VO2max

干预措施: Exercise - 85% (Other)

结局指标

主要结局

Diffusing Capacity for Carbon Monoxide

时间窗: Dopamine (Day 1), Metoclopramide (Day 2), Placebos (Day 3) *order randomized

Roughton and Forster's Three FIO2 DLCO Method at Rest, 60% of Vo2max, and 85% of Vo2max

Change in Pulmonary Capillary Blood Volume

时间窗: Dopamine (Day 1), Metoclopramide (Day 2), Placebos (Day 3) *order randomized

Roughton and Forster's Three FIO2 DLCO Method at Rest, 60% of Vo2max, and 85% of Vo2max

Pulmonary Artery Systolic Pressure

时间窗: Dopamine (Day 1), Metoclopramide (Day 2), Placebos (Day 3) *order randomized

Non-invasive estimation using Doppler echocardiography at Rest \& 60% of Vo2max

Cardiac Output

时间窗: Dopamine (Day 1), Metoclopramide (Day 2), Placebos (Day 3) *order randomized

Non-invasive estimation using trans-thoracic impedance cardiography at rest, 60% of Vo2max, and 85% of Vo2max

Pulmonary Vascular Resistance

时间窗: Dopamine (Day 1), Metoclopramide (Day 2), Placebos (Day 3) *order randomized

Calculation

次要结局

  • Exertional Dyspnea(Dopamine (Day 1), Metoclopramide (Day 2), Placebos (Day 3) *order randomized)
  • Exercise Tolerance(Dopamine (Day 1), Metoclopramide (Day 2), Placebos (Day 3) *order randomized)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

The Effect of Dopamine on Pulmonary Diffusion and... | 临床试验